Carisma Therapeutics (CARM) Projected to Post Quarterly Earnings on Thursday

Carisma Therapeutics (NASDAQ:CARM) is anticipated to announce its Q2 2025 earnings results before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $3.75 million for the quarter.

Carisma Therapeutics (NASDAQ:CARM) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.05). The firm had revenue of $3.65 million during the quarter, compared to the consensus estimate of $2.47 million. On average, analysts expect Carisma Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Carisma Therapeutics Stock Performance

CARM opened at $0.27 on Friday. The company has a market cap of $11.28 million, a PE ratio of -0.17 and a beta of 1.79. The stock has a 50-day moving average of $0.39 and a 200-day moving average of $0.35. Carisma Therapeutics has a 52-week low of $0.14 and a 52-week high of $1.27.

Analyst Ratings Changes

Several analysts have recently issued reports on CARM shares. Evercore ISI upgraded Carisma Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 15th. D. Boral Capital reiterated a “buy” rating and set a $1.00 price target on shares of Carisma Therapeutics in a research note on Friday. Four investment analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Carisma Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $1.93.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.